<?xml-stylesheet type="text/xsl" href="https://www.vetsurgeon.org/utility/feedstylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Bovela becomes market leading BVD vaccine</title><link>/b/veterinary-news/posts/bovela-becomes-market-leading-bvd-vaccine</link><description> Boehringer Ingelheim reports that Bovela, the BVD vaccine it launched in March 2015, became the market leader in terms of share of sales per month 1 in July 2017. 
 Matt Yarnall from Boehringer Ingelheim said: &amp;quot;This is fantastic news for Bovela which</description><dc:language>en-US</dc:language><generator>Telligent Community 10</generator></channel></rss>